Renalytix plc

Company Profile

Company website
Sector
Medical Equipment and Services (Medical Equipment)
Description

Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

Investor Access

30 Jun
Event information

Management will report its third quarter fiscal 2022 financial results

Venue
Time
30th June 2022
Financial Calendar
 Event  Date
Year End 30 June
Half  Year End 31 December
Preliminary Results* October
Interim Results* March
AGM* December

* Months based on previous announcements of this kind